Characteristics of asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) patients in the asthma/COPD study population# according to different ACOS definitions

ACOS Definition
Patients n7575444976322
Age years57±657±657±655±757±756±6
BMI kg·m−227±527±528±629±627±527±5
Waist-hip ratio0.89±0.080.89±0.080.90±0.080.94±0.090.90±0.080.90±0.08
Physical activity MET·week–133 (13–56)33 (13–56)27 (8–40)16 (8–41)18 (11–47)29 (13–49)
Lung function 
 FEV1/FVC <0.751513310010059
FeNO ≥45 ppb221257
Medication use 
 Combination LABA+ICS444456384840
Asthma duration years11 (2–24)11 (2–24)45 (19–52)40 (30–50)23 (3–40)21 (5–40)
Asthma onset before 40 years of age3939731006462
 Cardiovascular disease+774946
 Diabetes mellitus type 2668655

Data are presented as weighted mean±sd or median (interquartile range) for continuous outcomes and weighted proportion (%) for categorical outcomes, unless otherwise stated. BMI: body mass index; MET: metabolic equivalent of tasks; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; FeNO: exhaled nitric oxide fraction; SABA: short-acting β-agonist; LABA: long-acting β-agonist; SAMA: short-acting muscarinic antagonist; LAMA: long-acting muscarinic antagonist; ICS: inhaled corticosteroid; OCS: oral corticosteroid. #: n=846; : see main text and table 2 for ACOS definitions; +: myocardial infarction, angina, congestive heart failure, peripheral vascular disease. Statistically significant differences are given in italics.